Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07816367 is registered in ClinicalTrials.gov with Kallyope Inc. as lead sponsor.

NCT NCT07816367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Lead sponsor
Kallyope Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
October 2, 2026
Completion date
December 31, 2027
Enrollment
1,500 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

migraine